Skip to main content

Vanderbilt Vaccine Center Archives

Crowe receives national award for COVID antibody research

Mar. 31, 2022—Vanderbilt's James Crowe Jr., MD, and Michel Nussenzweig, MD, PhD, of The Rockefeller University, have been jointly awarded the 2022 Harrington Prize for Innovation in Medicine for “groundbreaking work” that enabled the use of human antibodies to treat COVID-19.

Read more


Technique hastens COVID-19 antibody discovery

Mar. 10, 2022—Optimization of a technique developed at Vanderbilt University Medical Center enables rapid and efficient identification of neutralizing monoclonal antibodies against the virus that causes COVID-19.

Read more


Research Staff Awards honor those who help drive science forward

Mar. 9, 2022—Laboratory and administrative personnel at Vanderbilt University Medical Center were honored March 4 for research excellence during the 18th annual Research Staff Awards Ceremony.

Read more


Pandemic leads to broader use of monoclonal antibodies

Feb. 17, 2022—Antiviral drugs and coronavirus-fighting monoclonal antibodies, including those discovered at Vanderbilt University Medical Center, remain crucially important in the continuing fight against COVID-19.

Read more


Patient receives antibodies discovered at Vanderbilt to prevent COVID-19 illness

Dec. 23, 2021—On Dec. 22, Caroline Davis of Nashville became the first patient at Vanderbilt University Medical Center to receive injections of a new antibody combination to protect her from COVID-19.

Read more


Antibodies discovered at Vanderbilt for prevention of COVID-19 granted FDA emergency use authorization

Dec. 9, 2021—The U.S. Food and Drug Administration granted emergency use authorization (EUA) to the global biopharmaceutical company AstraZeneca for a long-acting antibody combination which  protects against COVID-19, discovered last year at Vanderbilt University Medical Center.

Read more


VUMC researchers a step closer to broad ebolavirus protection

Oct. 28, 2021—  by Bill Snyder A combination of two broadly acting monoclonal antibodies isolated by researchers at Vanderbilt University Medical Center protected non-human primates from ebolavirus disease, which causes severe and often-fatal hemorrhagic fever in humans. Their findings, published this week in the journal Cell, bring closer to development the first clinical therapy effective against all...

Read more


Zost honored for research on COVID-19, other life-threatening viral diseases

Oct. 28, 2021—Vanderbilt's Seth Zost, PhD, has been awarded a major international prize for his research on COVID-19 and other life-threatening viral diseases. 

Read more


AstraZeneca seeks emergency approval for COVID-19 antibodies isolated at VUMC

Oct. 5, 2021—Biopharmaceutical company AstraZeneca has requested emergency use authorization (EUA) from the U.S. Food and Drug Administration for a long-acting antibody combination originally developed at Vanderbilt University Medical Center to protect against COVID-19.

Read more


“Ultra-potent” antibody against COVID-19 variants isolated at VUMC

Sep. 22, 2021—A technology developed at Vanderbilt has led to the discovery of an “ultra-potent” monoclonal antibody against multiple variants of SARS-CoV-2, the virus responsible for COVID-19, including the delta variant.

Read more


VUMC antibodies help neutralize two deadly viruses: study

Sep. 8, 2021—Vanderbilt researchers have isolated monoclonal antibodies that prevent severe illness and death caused by two emerging and deadly viruses called Nipah and Hendra.

Read more


COVID-19 antibody ‘cocktail’ discovered at VUMC protects chronically ill: study

Aug. 20, 2021—A monoclonal antibody cocktail against the COVID-19 virus discovered at Vanderbilt University Medical Center and developed by AstraZeneca reduced the risk of symptoms in a study of immunocompromised and chronically ill adults later exposed to the virus by 77%, the company announced today.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more